Virtual Clinician Research Tool (VCRT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01408758|
Recruitment Status : Completed
First Posted : August 3, 2011
Last Update Posted : February 28, 2017
|Condition or disease||Intervention/treatment||Phase|
|Elevated Risk of Cardiovascular Disease Tobacco Dependence||Other: Virtual Clinician Research Tool (VCRT) Other: No VCRT, only physician counseling at visits||Not Applicable|
Hypercholesterolemia and tobacco use interact to increase cardiovascular disease (USDHHS 1990; 2004). Smoking is a cause of metabolic syndrome and diabetes (Eliasson, 2003; Hu et al., 2001; Weitzman et al., 2005). Smokers live on average 13 years less than non-smokers (USDHHS, 2004), and tobacco remains the number one health threat in the United States (Mokdad, Marks, Stroup, & Gerberding, 2004). The Public Health Service (PHS) has published a Guideline for Tobacco Dependence Treatment (Fiore, 2000; Fiore et al., 2008). Hypercholesterolemia is a major risk for cardiovascular disease, and effective treatment with lifestyle and medications lower the risk of cardiovascular events including sudden death, myocardial infarction, and stroke. The National Cholesterol Education Program (NCEP) has published clinical guidelines for its management (Brown, 2004). These include recommendations for therapeutic lifestyle change and medications.
The specific aims of the proposed work are: first, to determine abstinence from tobacco at 6-months and lower LDL-cholesterol from baseline to 6-months for patients assigned the VCRT in addition to the clinician compared to those just receiving clinician care; second, to test for increase in medication use (number of days of medication use-for tobacco dependence mediations and for statin medications for cholesterol) for those receiving the VCRT + clinician; third, to examine the self-determination process model, expanded to include autonomous motivation and perceived competence for medication adherence and actual adherence to promote maintained abstinence and lower LDL-cholesterol.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||79 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Creating a Virtual Clinician Research Tool|
|Study Start Date :||January 2011|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||June 2012|
This group will have 2 visits with a study physician in addition to using the VCRT.
Other: Virtual Clinician Research Tool (VCRT)
The Virtual Clinician Research Tool (VCRT) will use Self-Determination Theory (SDT) to guide the process or style of how two national guidelines (one for hyperlipidemia, 1 for tobacco dependence)will be operationalized into a virtual format that patients can access online using any internet connected personal computer to develop their plan for change (in this project regarding tobacco or nutrition).
This group will have 2 visits with study physician only, no VCRT.
Other: No VCRT, only physician counseling at visits
- Tobacco abstinence or lowered LDL cholesterol [ Time Frame: 6 months ]abstinence from tobacco at 6-months and lower LDL-cholesterol from baseline to 6-months for patients assigned the VCRT in addition to the clinician compared to those receiving standard clinician care;
- increase in medication use [ Time Frame: 6 months ]increase in medication use (number of days of medication use-for tobacco dependence mediations and for statin medications for cholesterol) for those receiving the VCRT + clinician;
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01408758
|United States, New York|
|University of Rochester Medical Center Healthy Living Center|
|Rochester, New York, United States, 14607|
|Principal Investigator:||Geoffrey C. Williams, M.D., Ph.D.||University of Rochester|